Quantum Biopharma Ltd (QNTM)

Mon, 18 May 2026 03:00:00 -0400 - 3 days ago

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Thu, 07 May 2026 07:00:00 -0400 - 14 days ago

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Mon, 27 Apr 2026 19:45:00 -0400 - 23 days ago

Quantum BioPharma Provides Corporate Update

Wed, 22 Apr 2026 09:16:00 -0400 - 4 weeks ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

2026-04-01T12:25:14.000Z - 7 weeks ago

Quantum BioPharma submits Lucid-21-302 new drug application to the FDA

Wed, 01 Apr 2026 08:02:00 -0400 - 7 weeks ago

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

2026-03-30T12:47:57.000Z - 7 weeks ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

2026-03-30T12:28:19.000Z - 7 weeks ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

Mon, 30 Mar 2026 07:50:00 -0400 - 7 weeks ago

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Fri, 27 Mar 2026 19:30:00 -0400 - 7 weeks ago

Quantum Biopharma Provides Corporate Update

Fri, 27 Mar 2026 08:10:00 -0400 - 7 weeks ago

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status

Mon, 23 Mar 2026 08:24:00 -0400 - 2 months ago

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Fri, 20 Mar 2026 19:35:00 -0400 - 2 months ago

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Wed, 11 Mar 2026 19:55:00 -0400 - 2 months ago

Quantum BioPharma Provides Corporate Update

Thu, 19 Feb 2026 19:29:00 -0500 - 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Thu, 19 Feb 2026 12:00:00 -0500 - 3 months ago

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Tue, 17 Feb 2026 13:55:00 -0500 - 3 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 12:59:00 -0500 - 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Tue, 17 Feb 2026 09:41:00 -0500 - 3 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Thu, 12 Feb 2026 16:02:00 -0500 - 3 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Tue, 03 Feb 2026 13:12:00 -0500 - 3 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Mon, 02 Feb 2026 10:46:00 -0500 - 3 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

Tue, 27 Jan 2026 13:42:00 -0500 - 4 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Dec 23, 2025, 8:00 AM EST - 5 months ago

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Mon, 22 Dec 2025 09:00:00 -0500 - 5 months ago

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Dec 10, 2025, 8:00 PM EST - 5 months ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

2025-12-01T12:15:18.000Z - 6 months ago

Quantum BioPharma announces airing of news segment on manipulation lawsuit

Nov 27, 2025, 4:00 PM EST - 6 months ago

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Nov 26, 2025, 9:30 AM EST - 6 months ago

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

2025-11-07T12:12:42.000Z - 6 months ago

Quantum BioPharma reports Q3 EPS ($1.25) vs. (4.37) last year

2025-11-07T12:11:35.000Z - 6 months ago

Quantum BioPharma sees cash runway beyond March 2027

Nov 7, 2025, 7:00 AM EST - 6 months ago

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Oct 31, 2025, 7:51 PM EDT - 7 months ago

Quantum BioPharma Ltd. Provides Corporate Update

Oct 29, 2025, 9:00 PM EDT - 7 months ago

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 23, 2025, 8:15 AM EDT - 7 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

2025-10-20T12:40:40.000Z - 7 months ago

Quantum BioPharma announces expiration of warrants held by hedge funds

Oct 20, 2025, 8:30 AM EDT - 7 months ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 14, 2025, 8:15 AM EDT - 7 months ago

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

Oct 9, 2025, 6:00 PM EDT - 7 months ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 9, 2025, 5:40 PM EDT - 7 months ago

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

2025-10-08T12:15:28.000Z - 8 months ago

Quantum BioPharma offers cash reward up to $7M for market manipulation proof

Oct 8, 2025, 8:00 AM EDT - 8 months ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 7, 2025, 11:00 AM EDT - 8 months ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

2025-10-03T11:10:25.000Z - 8 months ago

Quantum BioPharma announces record date for special dividend distribution

Oct 3, 2025, 7:00 AM EDT - 8 months ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

2025-10-02T12:00:38.000Z - 8 months ago

Quantum BioPharma receives final reports for two studies of Lucid-21-302

Oct 2, 2025, 7:57 AM EDT - 8 months ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

2025-10-01T11:55:37.000Z - 8 months ago

Quantum BioPharma appoints Jack Antel as clinical development advisor

Oct 1, 2025, 7:50 AM EDT - 8 months ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

2025-09-29T11:45:06.000Z - 8 months ago

Quantum BioPharma announces Annual General, Special Meeting results

Sep 29, 2025, 7:40 AM EDT - 8 months ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 26, 2025, 8:00 PM EDT - 8 months ago

Quantum BioPharma Announces Corporate Updates

Sep 24, 2025, 8:30 AM EDT - 8 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 18, 2025, 8:10 AM EDT - 8 months ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 12, 2025, 7:50 AM EDT - 8 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 10, 2025, 7:00 AM EDT - 9 months ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Aug 11, 2025, 6:32 PM EDT - 10 months ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 7:40 AM EDT - 10 months ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

2025-08-08T12:10:18.000Z - 10 months ago

Quantum BioPharma announces results from study on PET tracer

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Aug 5, 2025, 7:34 AM EDT - 10 months ago

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Aug 4, 2025, 7:33 AM EDT - 10 months ago

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

Jul 31, 2025, 7:24 AM EDT - 10 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

Jul 22, 2025, 7:00 AM EDT - 10 months ago

Quantum BioPharma Makes Strategic Investment in GameStop Corp.

GME

Jun 27, 2025, 4:30 PM EDT - 11 months ago

Quantum BioPharma Announces Private Placement

Jun 26, 2025, 7:30 AM EDT - 11 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

Jun 18, 2025, 9:19 AM EDT - 1 year ago

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

Jun 13, 2025, 7:00 AM EDT - 1 year ago

Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

Jun 3, 2025, 7:50 AM EDT - 1 year ago

Quantum BioPharma Clarifies It Has Not Changed Its Name

Jun 2, 2025, 1:47 PM EDT - 1 year ago

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients

May 30, 2025, 7:00 AM EDT - 1 year ago

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

May 29, 2025, 7:30 AM EDT - 1 year ago

Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.